Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)

• Company Description    Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. Number of Employees: 323

• Price / Volume Information    Yesterday's Closing Price: $68.20 Daily Weekly Monthly 20 Day Moving Average: 547,212 shares Shares Outstanding: 42.45 (millions) Market Capitalization: $2,895.03 (millions) Beta: 0.82 52 Week High: $76.81 52 Week Low: $38.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.22% -2.83% 12 Week 29.36% 23.09% Year To Date 23.17% 6.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15440 LAGUNA CANYON ROAD SUITE 160 - IRVINE,CA 92618 USA ph: 949-418-1801 fax: - dnakasone@tarsusrx.com http://www.tarsusrx.com

• General Corporate Information    Officers Bobak Azamian - President; Chief Executive Officer and Chairman Jeffrey Farrow - Chief Financial Officer and Chief Strategy Officer Scott Morrison - Director Bhaskar Chaudhuri - Director Andrew Goldberg - Director Peer Information Tarsus Pharmaceuticals, Inc. (CORR.) Tarsus Pharmaceuticals, Inc. (RSPI) Tarsus Pharmaceuticals, Inc. (CGXP) Tarsus Pharmaceuticals, Inc. (BGEN) Tarsus Pharmaceuticals, Inc. (GTBP) Tarsus Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87650L103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/24/26 Share - Related Items Shares Outstanding: 42.45 Most Recent Split Date: (:1) Beta: 0.82 Market Capitalization: $2,895.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.62 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 55.80% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.64 Price/Cash Flow: - Price / Sales: 7.91 EPS Growth vs. Year Ago Period: 50.82% vs. Previous Quarter: 37.50% Sales Growth vs. Year Ago Period: 146.68% vs. Previous Quarter: 15.62% ROE 09/30/25 - -26.29 06/30/25 - -32.36 03/31/25 - -39.72 ROA 09/30/25 - -17.02 06/30/25 - -21.04 03/31/25 - -25.74 Current Ratio 09/30/25 - 4.29 06/30/25 - 5.26 03/31/25 - 5.57 Quick Ratio 09/30/25 - - 06/30/25 - 5.21 03/31/25 - 5.54 Operating Margin 09/30/25 - -22.17 06/30/25 - -31.13 03/31/25 - -44.91 Net Margin 09/30/25 - -22.17 06/30/25 - -31.13 03/31/25 - -44.91 Pre-Tax Margin 09/30/25 - -22.17 06/30/25 - -31.13 03/31/25 - -44.91 Book Value 09/30/25 - 7.89 06/30/25 - 7.92 03/31/25 - 8.15 Inventory Turnover 09/30/25 - 7.57 06/30/25 - 6.51 03/31/25 - 6.32 Debt-to-Equity 09/30/25 - 0.22 06/30/25 - 0.22 03/31/25 - 0.21 Debt-to-Capital 09/30/25 - 17.74 06/30/25 - 17.82 03/31/25 - 17.37

Powered by Zacks Investment Research ©